ERBB2 and invasive breast carcinoma: Considering these encouraging observations, NRG BR008 (HERO) is a phase III randomized clinical trial expected to launch in the first quarter of 2023 that will include women ≥ 40 years diagnosed with early-stage, low-risk HER2-positive invasive breast cancer (those with pT1N0 receiving chemotherapy or those with clinically < 3 cm node-negative cancer achieving pathological complete responses with neoadjuvant chemotherapy and HER2-targeted therapies).